🔎 Trials Near Me

Home › Overactive Bladder › NCT06797245

APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women

Recruiting

The APPROVE Trial: A Randomized Controlled Trial Evaluating the Efficacy and Safety of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women

Who can join

Ages 22 and older · Women

Full eligibility criteria
Inclusion Criteria:

* Women ≥ 22 years old
* Bothersome OAB symptoms (defined as bother rating ≥ 5 on ICIQ-FLUTS question #3b or #9b)
* English-speaking
* Willing to forego other treatment outside of medications for the 8-week trial period
* Use of at least one mobile App

Exclusion Criteria:

* Stress-predominant mixed urinary incontinence (defined as QUID stress score \> QUID urge score)
* Voiding dysfunction defined as response ≥ 2 on ICIQ-FLUTS question #7a
* Bladder pain defined as response ≥ 2 on ICIQ-FLUTS question #4a
* Use of an OAB medication (anticholinergic or beta-agonist) within the past two weeks
* Currently using intermittent or indwelling catheter
* History of bladder/urethral, colon/anal, or cervical cancer
* Current or prior use of sacral neuromodulation, tibial stimulation or onabotulinum toxin type A intradetrusor injection
* Currently taking antibiotics/drugs for urinary tract infection\^
* Currently undergoing or unwilling to forego pelvic floor physical therapy with a physical therapist or prescription device for the 8-week intervention period
* Planning surgery for pelvic organ prolapse within 12 months of randomization
* Pelvic surgery within the past 6 months
* Planning to undergo pessary fitting °

  * Those on antibiotics for urinary tract infection will be eligible for enrollment 2 weeks after completing antibiotic therapy with subjective resolution of UTI symptoms °Will be eligible after completing pessary fitting

https://researchdata.medstar.net/redcap/surveys/?s=MM7WN7EXACX4PNXJ

About the study

The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therapeutic (PDTx) app called RiSolve compared to standard behavioral education (handouts).

What is being tested

Sponsor: Medstar Health Research Institute · Participants: 596 · Started: Mar 17, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06797245

Locations in the U.S.

AlabamaUniversity of Alabama at Birmingham, Birmingham
CaliforniaStanford University, Palo Alto
District of ColumbiaMedStar Health, Washington D.C.
IllinoisUniversity of Chicago, Chicago
North CarolinaAtrium Health Wake Forest Baptist, Winston-Salem
PennsylvaniaAllegheny Health, Pittsburgh
South CarolinaMedical University of South Carolina Health, Charleston
TexasUT Southwestern Medical Center, Dallas
WisconsinUniversity of Wisconsin, Madison

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.